Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
Information source: Samsung Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Unstable Angina; Coronary Artery Bypass Graft; Dexmedetomidine; Lidocaine; Myocardial Injury; Arrhythmia; Blood Electrolyte Balance
Intervention: Lidocaine infusion (Drug); Dexmedetomidine infusion (Drug)
Phase: N/A
Status: Completed
Sponsored by: Samsung Medical Center
Summary
The aim of the present study is to compare the antiarrhythmic and myocardial protective
effect between lidocaine, dexmedetomidine, and their combined infusion in subjects
undergoing coronary artery bypass graft.
Clinical Details
Official title: The Comparison of Antiarrhythmic and Myocardial Protective Effect Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)
Primary outcome: Myocardial injury markerMyocardial injury marker Myocardial injury marker
Secondary outcome: The blood sodium, potassium, calcium levelThe incidence of arrhythmia during and after the surgery Postoperative ICU stay, Hospital stay, Extubation time Inotropics use during and after the surgery The incidence of hypokalemia
Detailed description:
Lidocaine has been reported to have an antiarrhythmic and myocardial protective effect. A
previous study has reported that low-dose lidocaine infusion can decrease the incidence of
ventricular fibrillation and tachycardia during the first 24 hours after coronary artery
bypass graft (CABG). A recent study also reported that the lidocaine infusion during CABG
could decrease the myocardial injury by measuring the CK-MB and Troponin-I blood level.
Dexmedetomidine is an alpha-2 agonist and reduces the sympathetic tone and neuroendocrine
stress response. Dexmedetomidine was reported to have a cardioprotective effect by a
previous animal study. However, there was no clinical study evaluating the cardioprotective
effect of dexmedetomidine.
Therefore, we are trying to evaluate and compare the antiarrhythmic and myocardial
protective effect between lidocaine, dexmedetomidine, and their combined infusion in
subjects undergoing coronary artery bypass graft.
Eligibility
Minimum age: 20 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Those undergoing off-pump coronary artery bypass graft during the study period in
Samsung Medical Center
Exclusion Criteria:
- Any patients with plasma aldosterone, or glucocorticoid disorder including primary
hyperaldosteronism, renovascular hypertension, rennin-secreting tumor, salt-wasting
renal disease, Cushing syndrome
- Patients with recent exogenous steroid administration or previous diuretics therapy
- Patients with recent myocardial infarction
- Those undergoing unplanned cardiopulmonary bypass during the surgery
Locations and Contacts
Samsung Medical Center, Seoul 135-710, Korea, Republic of
Additional Information
Starting date: September 2012
Last updated: October 24, 2014
|